Stockscreener 앱 받기
6.45
4.59%
-0.31
시간 외 거래:
6.36
-0.09
-1.40%
전일 마감가:
$6.76
열려 있는:
$6.76
하루 거래량:
1.34M
Relative Volume:
1.10
시가총액:
$803.74M
수익:
-
순이익/손실:
$-167.48M
주가수익비율:
-3.3077
EPS:
-1.95
순현금흐름:
$-197.47M
1주 성능:
-18.66%
1개월 성능:
-11.28%
6개월 성능:
-60.65%
1년 성능:
-60.62%
1일 변동 폭
$6.35
$6.91
1주일 범위
$6.26
$7.955
52주 변동 폭
$6.26
$17.14
Day One Biopharmaceuticals Inc Stock (DAWN) Company Profile
명칭
Day One Biopharmaceuticals Inc
전화
650 484-0899
주소
2000 SIERRA POINT PARKWAY, SUITE 501, BRISBANE
DAWN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DAWN
Day One Biopharmaceuticals Inc
|
6.45 | 803.74M | 0 | -167.48M | -197.47M | -1.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Day One Biopharmaceuticals Inc Stock (DAWN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-09 | 재확인 | Needham | Buy |
| 2024-08-01 | 업그레이드 | BofA Securities | Underperform → Buy |
| 2024-04-24 | 재확인 | Needham | Buy |
| 2023-04-25 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2023-02-08 | 개시 | CapitalOne | Overweight |
| 2023-02-03 | 개시 | Oppenheimer | Perform |
| 2022-12-15 | 개시 | H.C. Wainwright | Buy |
| 2022-12-14 | 개시 | Needham | Buy |
| 2022-12-05 | 개시 | Goldman | Buy |
| 2022-12-01 | 개시 | BofA Securities | Buy |
모두보기
Day One Biopharmaceuticals Inc 주식(DAWN)의 최신 뉴스
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Purchased by Dimensional Fund Advisors LP - Defense World
Research Analysts Issue Forecasts for DAWN Q2 Earnings - Defense World
Needham & Company LLC Cuts Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target to $27.00 - Defense World
Research Analysts Set Expectations for DAWN Q2 Earnings - Defense World
Is Day One Biopharmaceuticals, Inc. (DAWN) the Low Risk High Reward Stock Set to Triple by 2030? - Insider Monkey
Analysts Issue Forecasts for DAWN Q1 Earnings - Defense World
10 Low Risk High Reward Stocks Set to Triple by 2030 - Insider Monkey
Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Up After Earnings Beat - Defense World
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Sold by Mariner LLC - Defense World
Day one biopharmaceuticals highlights OJEMDA revenue growth and pipeline progress in Q1 2025 - MSN
Day One Biopharmaceuticals (NASDAQ:DAWN) Reaches New 12-Month Low Following Analyst Downgrade - Defense World
Day One Biopharma’s Earnings Call Highlights Growth - TipRanks
Day One Biopharmaceuticals (DAWN) Target Price Adjusted to $26 | DAWN Stock News - GuruFocus
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Q1 2025 Earnings Call Transcript - Insider Monkey
MetLife Investment Management LLC Raises Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Day One Biopharmaceuticals earnings beat by $0.07, revenue fell short of estimates - Investing.com Canada
Day One Biopharmaceuticals Reports Strong Q1 2025 Results - TipRanks
Day One Biopharmaceuticals Inc (DAWN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ... By GuruFocus - Investing.com Canada
Day One Reports First Quarter 2025 Financial Results and Corporate Progress - GlobeNewswire
Earnings call transcript: Day One Biopharmaceuticals beats Q1 2025 EPS forecast - Investing.com
Day One Biopharmaceuticals Q1 2025 slides: OJEMDA revenue grows 11% amid market challenges - Investing.com Canada
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Day One Biopharmaceuticals, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:DAWN) - Seeking Alpha
Day One Biopharmaceuticals Inc (DAWN) Q1 2025 Earnings Report Pr - GuruFocus
Day One Biopharmaceuticals Inc (DAWN) Q1 2025 Earnings Report Preview: What to Expect - GuruFocus
Day One Biopharmaceuticals (DAWN) Projected to Post Quarterly Earnings on Tuesday - Defense World
Holdings of Day One Biopharmaceuticals Inc (DAWN) are aligned with the stars - Sete News
Wells Fargo & Company MN Sells 4,744 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Is Day One Biopharmaceuticals Inc (DAWN) worth investing in despite its overvalued state? - uspostnews.com
Examining the Potential Price Growth of Day One Biopharmaceuticals Inc (DAWN) - knoxdaily.com
Market Momentum Report: Xeris Biopharma Holdings Inc (XERS)’s Positive Close at 4.41 - DWinneX
Azitra Inc (AZTR)’s Day in Review: Closing at 0.30, Down by -6.51 - DWinneX
SuperCom Ltd (SPCB)’s Day in Review: Closing at 6.19, Down by -22.04 - DWinneX
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Stock Holdings Decreased by Legal & General Group Plc - Defense World
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Average Rating of “Buy” by Analysts - Defense World
DAWN Stock Sees Surge of Approximately 16.86% in Last Five Days - knoxdaily.com
Wedbush Brokers Decrease Earnings Estimates for DAWN - Defense World
How did Metsera Inc (MTSR) fare last session? - uspostnews.com
Market Highlights: Day One Biopharmaceuticals Inc (DAWN) Ends on a High Note at 7.14 - DWinneX
Day One to Report First Quarter 2025 Financial Results Tuesday, May 6, 2025 - GlobeNewswire
Day One Q1 2025 Earnings: Live Webcast Details and Key Updates Coming May 6 - Stock Titan
What is Day One Biopharmaceuticals Inc (DAWN) Stock Return on Shareholders’ Capital? - Sete News
Finance Watch: No Big Post-ASCO Follow-On Frenzy, But Biotech Had A Good Week - insights.citeline.com
Geode Capital Management LLC Has $18.54 Million Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
BofA Adjusts Price Target on Day One Biopharmaceuticals to $21 From $24, Keeps Buy Rating - marketscreener.com
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Sold by Corebridge Financial Inc. - Defense World
Vanguard Group Inc. Lowers Stock Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Day One Biopharmaceuticals Pullback Is A Potential Buying Opportunity - Seeking Alpha
Day One Biopharmaceuticals, Inc. (DAWN): Among Stocks Under $10 that Will Triple - MSN
KLP Kapitalforvaltning AS Invests $150,000 in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
10 Stocks Under $10 that Will Triple - Insider Monkey
Day One Biopharmaceuticals Inc (DAWN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.84%
0.15%
자본화:
|
볼륨(24시간):